KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Deffered Revenue (2016 - 2023)

Historic Non-Current Deffered Revenue for Halozyme Therapeutics (HALO) over the last 15 years, with Q3 2023 value amounting to $2.3 million.

  • Halozyme Therapeutics' Non-Current Deffered Revenue fell 2047.3% to $2.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.3 million, marking a year-over-year decrease of 2047.3%. This contributed to the annual value of $2.3 million for FY2022, which is 1094.86% down from last year.
  • According to the latest figures from Q3 2023, Halozyme Therapeutics' Non-Current Deffered Revenue is $2.3 million, which was down 2047.3% from $2.3 million recorded in Q2 2023.
  • Halozyme Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $4.0 million during Q4 2020, with a 5-year trough of $641000.0 in Q3 2020.
  • Its 5-year average for Non-Current Deffered Revenue is $2.5 million, with a median of $2.4 million in 2021.
  • In the last 5 years, Halozyme Therapeutics' Non-Current Deffered Revenue plummeted by 7509.98% in 2019 and then skyrocketed by 29469.58% in 2021.
  • Over the past 5 years, Halozyme Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $1.2 million in 2019, then soared by 222.85% to $4.0 million in 2020, then tumbled by 37.16% to $2.5 million in 2021, then fell by 10.95% to $2.3 million in 2022, then changed by 0.0% to $2.3 million in 2023.
  • Its Non-Current Deffered Revenue was $2.3 million in Q3 2023, compared to $2.3 million in Q2 2023 and $2.3 million in Q1 2023.